### **Overview** Panacea Biotec Ltd is an innovation-driven, integrated biopharmaceutical company with over four decades of leadership in vaccine development, pharmaceuticals, nutrition, and wellness. Headquartered in India, the company has established itself as a global health player through pioneering scientific contributions, particularly in **pediatric immunization**, and has expanded into adjacent health domains with a focus on newborns, mothers, and long-term wellness. The company's mission centers on delivering **affordable, high-quality, and science-backed healthcare solutions** across emerging and developed markets, supported by advanced R&D, robust manufacturing infrastructure, and strategic global partnerships. --- ### **Strategic Focus & Business Segments** Panacea Biotec operates through three core business verticals: 1. **Vaccines** – Flagship business, contributing the majority of revenue. 2. **Pharmaceutical Formulations** – Complex generics for chronic diseases in regulated and emerging markets. 3. **Nutrition & Baby Care** – A rapidly growing segment focused on early-life health and preventive care. Additionally, Panacea Biotec is expanding its footprint in **nutraceuticals, wellness, and preventive lifestyle healthcare** through strategic acquisitions and in-house innovation. --- ### **Recent Strategic Developments (as of Sep 2025)** #### **1. Expansion into Infant Health & Hygiene: NikoMom Launch** - Launched **NikoMom**, a new brand offering **infant diapers and 99.9% water-based wet wipes**, expanding into newborn hygiene. - This move aligns with the company’s core mission of **child-centric health**, reinforcing its continuum from **vaccines to early nutrition and hygiene**. - Products are available via: - E-commerce: Amazon, Flipkart, Tata 1mg - Direct-to-Consumer (D2C): *www.7Nshop.com* - Pan-India retail expansion via LEAP SBU. #### **2. Child-Centric Health Ecosystem** - Positioned as a **"continuum of care"** brand from infancy through adulthood. - Leverages **deep trust with pediatricians** (via over 150 sales reps and 10,000 pediatricians reached) to drive product adoption. - Plans to expand future offerings into **women’s health and adult nutrition**, creating a lifelong health engagement platform. #### **3. Retail & Market Expansion via LEAP SBU** - Launched a dedicated **LEAP (Leveraging Excellence in Access & Penetration) Strategic Business Unit**. - Focus: Deepen rural, semi-urban, and urban retail footprint across India. - Strengthens **last-mile distribution** for flagship brands like **NikoMom and ChilRun®**. - Integrated CFA network with D2C delivery system for hybrid scalability and consumer convenience. #### **4. Entry into Nutraceuticals: Power Gummies Acquisition** - Acquired **Power Gummies**, including IP, formulations, and digital assets. - Targets **millennials and Gen Z** with science-backed gummy supplements for: - Hair, skin, nails - Weight management - Sleep support - Represents a key step in Panacea’s **preventive and lifestyle healthcare strategy**. --- ### **Vaccines – Core Strength and Global Impact** #### **Leadership in Pediatric Immunization** - **One of the largest suppliers of oral polio vaccines (OPV)** globally; delivered **over 10 billion doses**. - Instrumental in eradicating polio in India, reducing cases from 10,000 to zero. - Key vaccine supplier to **UNICEF, PAHO, WHO, GAVI**, and national governments across **~30 countries**. #### **Flagship Vaccine Portfolio** | Product | Innovation | |--------|------------| | **EasySix®** | World’s first **fully liquid wP-IPV-based hexavalent vaccine (DTwP-HepB-Hib-IPV)**. Market leader in India. | | **EasyFive-TT®** | First **fully liquid pentavalent vaccine**; WHO-prequalified, supplied globally. | | **EasyFourPol®** | First **fully liquid pentavalent (DTwP-IPV-Hib)** vaccine, launched in 2023–24. | | **b-OPV** | Bivalent oral polio vaccine; key contributor to global eradication. | - **EasySix®** is listed under the **Continental Listing of Human Medicinal Products** by the **African Medicines Agency (AMA)**, enabling fast-tracked approvals in up to **29 African nations**. #### **Key Vaccine Pipeline (Under Clinical Development)** - **DengiAll®**: Single-dose, **tetravalent dengue vaccine**; in **Phase III trials** (collaboration with ICMR). - Demonstrated protection across all serotypes, no ADE risk. - Anticipated launch in 2026 (subject to approval). - **NuCoVac®11**: **11-valent pneumococcal conjugate vaccine**; **Phase II/III trials underway**. - **VaxiPox™**: **Multi-epitope subunit Mpox vaccine** (development with BRIC-THSTI). - Designed to be **safer for children and immunocompromised individuals**. - Targets the growing **$1.2–2.5 billion global Mpox vaccine market**. - **Broadly Protective Betacoronavirus Vaccine**: Nanoparticle-based candidate, supported by **CEPI**; aims for **100-day pandemic response capability**. - **TedShot®**: Reduced-dose **Tetanus & Diphtheria vaccine**; approved in India, targeting ₹250 million private market. #### **Global Market Access & Registrations** - Vaccines registered in **16 countries**; applications in review in **17 more**. - Plans to **seek WHO prequalification** for pipeline vaccines to access **multilateral supply contracts**. - Active exports to Africa, Asia, and Latin America. --- ### **Pharmaceuticals – Global Reach & Complex Generics** #### **Domestic & International Presence** - Operated through **Panacea Biotec Pharma Limited (PBPL)** and **Panacea Biotec Germany GmbH (PBGG)**. - Exports to **~40 countries**, including U.S., Germany, Canada, Saudi Arabia, UAE, and South Africa. #### **Key Launches & Expansions** - **Valgapan (Valganciclovir)** launched in Germany via PBGG. - **PacliALL®** (nanoparticle-based generic of **Abraxane**) launched in Canada; ANDA filed in **11 EU countries**. - **Rizatriptan** relaunched in Saudi Arabia; presence re-established in Brazil after 8-year gap. #### **Product Pipeline & Regulatory Strategy** - Over **388 active international product registrations**; 48 dossiers under review; 50 more planned FY2025–26. - Plans to commercialize **Paclitaxel, Cyclosporine**, and other **complex generics** in the U.S. and EU. - Collaborations with **Apotex, Bionpharma, Breckenridge, and Natco** to expand international footprint. --- ### **R&D and Innovation Leadership** - **OneStream Research Centre (New Delhi)**: End-to-end vaccine development. - Capabilities: Genetic engineering, fermentation, purification, adjuvant development. - Developed **high-cell-density E. coli platform** for recombinant antigens. - **SAMPANN R&D Centre (Lalru, Punjab)**: Focus on pharmaceuticals and pediatric nutrition. - Over **1,500 patents filed globally**; recognized as **Thomson Reuters Top 50 Innovator (2015–2016)**. #### **Innovation Areas** - **Recombinant, conjugate, viral, DNA/RNA, and VLP-based vaccines**. - **Adjuvant Development**: Launched **EmulsiPan®**, an **open-access oil-in-water emulsion adjuvant**. - Used in preclinical trials for **Sarbecoronavirus vaccines** (e.g., Caltech NHP studies). - Enters a **$4.8 billion+ market**. --- ### **Manufacturing and Supply Chain Excellence** - **Integrated, dual-market supply chain**: - **Domestic (India)**: Retail and D2C focus via 2 central warehouses, 14 CFAs, ~1,500 distributors. - **Global**: Partners with top logistics providers, airlines, and customs agencies; ensures **cold chain integrity** for vaccines. - **Cold Chain Capabilities**: - **Vaccine Vial Monitors (VVMs)**, data loggers, Tyvek packaging. - Real-time tracking, **Track & Trace system**, and WHO-compliant documentation. - Manufacturing sites in: - **Lalru (Punjab)**: Vaccine drug substances (WHO-prequalified). - **Baddi (Himachal Pradesh)**: Formulations, nutrition products, and sterile injectables (US FDA-approved). #### **Capacity Expansion** - Secured **$20 million loan from U.S. DFC** to expand **wP-based hexavalent vaccine (EasySix®) production capacity**. - Expansion will support **UNICEF, PAHO, and GAVI** demand. - New capacity targeted for **global public health programs from 2025 onward**. --- ### **Nutrition Business: ChilRun® & Portfolio Expansion** - Launched **ChilRun®** pediatric nutrition line in June 2023: - **ChilRunfull®**, **ChilRun®7+**, **ChilRun® No Sucrose** - Available in **over 10,000 retail outlets** and e-commerce platforms. - Scientific validation: A **90-day post-marketing study** showed positive growth support in at-risk children. - New factory in Baddi: **6-ton/day capacity**, GMP-compliant. - Plans to expand into **baby cereals, gummies, bars, oils, and adult/women’s nutrition**. --- ### **Financial Highlights (FY 2024–25)** - **Consolidated Pharma & Nutrition Revenue**: ₹2,493 million (+25% YoY). - Export revenue: ₹1,838 million (+11%) - Domestic sales: ₹654 million (up from ₹340 million) - **Foreign Exchange Earnings**: ₹2,209.63 million (mostly exports). - **Royalty Income**: ₹20.63 million (e.g., from DengiAll® in-licensing agreement). --- ### **Growth Strategy** 1. **Internal Innovation**: - Advance **DengiAll®, NuCoVac®11, VaxiPox™, and Betacoronavirus vaccine** to commercialization. - File more ANDAs and expand complex generics portfolio. 2. **Geographic Expansion**: - Grow private market vaccine sales in India. - Expand exports to **50+ countries** through registration and partnerships. 3. **Portfolio Diversification**: - Broaden beyond pentavalent/hexavalent dependency. - Develop next-gen **conjugate, recombinant, and mRNA vaccines**. 4. **Strategic Partnerships**: - Collaborations with **ICMR, NIH (USA), CEPI, THSTI, Serum Institute**, and **global pharma firms**. - Licensing and co-development to accelerate pipeline. --- ### **Key Challenges** - **High R&D costs and long gestation periods**. - **Tender-dependent revenue**: Over-reliance on UNICEF/PAHO contracts. - **Concentration risk**: ~70–80% of vaccine revenue from **pentavalent and hexavalent vaccines**. ---